利巴韦林雾化联合免疫球蛋白治疗年龄小于3个月婴儿呼吸道合胞病毒感染疗效观察

Observation on the Efficacy of Ribavirin Atomization Combined with Immunoglobulin for the Treatment of Respiratory Syncytial Virus Infection in Infants Aged Below 3 Months

【目的】评价利巴韦林雾化联合免疫球蛋白治疗年龄小于3个月婴儿呼吸道合胞病毒（RSV）感染疗效。【方法】将入住本院治疗的年龄小于3个月婴儿呼吸道合胞病毒感染患儿100例按不同治疗方法分为联合治疗组和常规治疗组两组各50例，所有患儿均给予保持呼吸道通畅、止咳化痰、预防感染、维持内环境稳定等对症支持治疗，在此基础上联合治疗组给予利巴韦林雾化及免疫球蛋白（IVIG）静脉注射，常规组单用利巴韦林雾化，观察比较两组患儿的临床疗效。【结果】联合治疗组喘憋、呼吸急促持续时间显著短于常规组（P〈0．05）；肺部哆音消失时间明显早于常规组（P〈0．05）；总有效率（96．0％）显著高于常规组（82％）。【结论】利巴韦林雾化联合免疫球蛋白治疗年龄小于3个月婴儿婴儿呼吸道合胞病毒感染可明显提高临床疗效。

[Objective] To evaluate the efficacy of ribavirin atomization combined with immunoglobulin （IVIG） for the treatment of respiratory syncytial virus （RSV） infection in infants aged below 3 months. [Methods] According to different treatment methods, 100 infants（aged below 3 months） with RSV infection admitted in our hospital were divided into combination therapy group and routine therapy group with 50 cases in each group. All patients were given symptomatic supporting therapy including keeping respiratory tract un- obstructed, relieving cough and reducing sputum, preventing infection and maintaining homeostasis. Based on above therapy, the combination therapy group was given ribavirin atomization and IVIG intravenous injection, while the routine group was only given ribavirin atomization. Clinical efficacy was observed and compared be- tween 2 groups. [Results]The duration of wheeze and tachypnea in the combination therapy group was signifi- cantly shorter than that in the routine group（ P 〈0.05）, and the disappearance time of lung tale in the combi- nation therapy group was obviously earlier than that in the routine group（ P 〈0.05）. The total effective rate （96.0%） in the combination therapy group was markedly higher than that in the routine group （82%）. [Conclusion]Ribavirin atomization combined with IVIG for the treatment of RSV infection in infants aged be- low 3 months can obviously improve the clinical efficacy.